# Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis

> **NCT07719530** · PHASE2 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** The SHR-1139 injection
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07719530
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719530, "Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*